InnoCare focuses on discovering and developing innovative medicines to address serious diseases with significantly unmet medical needs, especially for the Chinese patients in the following therapeutic fields:
Systemic lupus erythematosus (SLE)
SLE is a serious and potentially fatal autoimmune disease that attacks healthy tissues. It disproportionately affects women and usually develops between the ages of 15 and 44. SLE can affect many parts of the body such as joints, skin, kidneys, lungs, the heart, and the brain. When common SLE symptoms appear (flare), they are manifested as swelling in the joints, joint pain, light sensitivity, fever, chest pain, hair loss, or fatigue.
It is estimated that approximately 800,000 to 1.5 million people are suffering from SLE in China. People of all races can contract the disease, but Chinese women have a 3-time higher incidence (number of new cases) rate than Caucasian women. At present, no cure is available and there is an urgent need for the research and development of highly specific and effective new drugs.
RA is a progressive inflammatory disease that affects the joints. Unless the inflammation is stopped or slowed, it worsens over time.
Arthritis medications play an essential role in controlling the progression and symptoms of RA. It is most effective to start the treatment soon after diagnosis, and the best medical care combines rheumatoid arthritis medications and other approaches. At present, Arthritis is primarily treated using biologics drugs, which are expensive and can only be administered through IV or IP.
Approximately 5-10 million people in China are suffering from the disease. There is an increasing need for cheaper drugs that can be more conveniently administered to patients.
Liver cancer is the second leading cause of cancer-related deaths worldwide, with HCC accountingfor most cases ofliver cancer. The highest incidences of HCC occur in regions such as China or Southeast Asia, where the endemic hepatitis B virus, or HBV, is more prevalent. Over the past two decades, the HCC incidence rate has tripled while the five-year survival rate has remained below 12%.
There are 700,000 new cases of HCC worldwide each year, but more than half of them are in China. Sorafenib is the only drug approved to treat HCC, and no other second line therapy has yet to be approved.
Gastric cancer is the fifth leading cause of cancer worldwide and the third leading cause of death from cancer, accounting for 7% of the cancer cases and 9% of cancer related deaths. Gastric cancer occurs most commonly in China and Eastern Asia, and men contract this disease twice as often as women do.
Chemotherapy and antibody based targeted therapy are the current leading treatment options other than surgery and radiation therapy. Patients will benefit tremendously from new treatment option of bioavailable small molecule drugs.